Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Autolus Therapeutics reported fourth quarter and full year 2025 financial results highlighted by $74.3 million in net product revenue for their CAR T cell therapy AUCATZYL, approved for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The company has launched AUCATZYL in the UK following positive NICE evaluation and expects conti…